



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	09/747,760
Filing Date	December 21, 2000
First Named Inventor	Glynne, Richard, et. al.
Art Unit	1639
Examiner Name	P. Ponnaluri
Attorney Docket Number	018547-046600US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PP	AA	ADACHI, TAKAHIRO, et al.; Cutting Edge: The B Cell Surface Protein CD72 Recruits the Tyrosine Phosphatase SHP-1 upon Tyrosine Phosphorylation; <i>The Journal of Immunology</i> ; 1998; pp. 4662-4665; Vol. 160	
	AB	ALESSI, DARIO R. et al.; PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase <i>in Vitro</i> and <i>in Vivo</i> ; <i>The Journal of Biological Chemistry</i> ; November 17, 1995; pp. 27489-27494; Vol. 270, No. 46	
	AC	COOKE, MICHAEL P., et al.; Immunoglobulin Signal Transduction Guides the Specificity of B Cell-T Cell Interactions and Is Blocked in Tolerant Self-reactive B Cells; <i>The Journal of Experimental Medicine</i> ; February 1994; pp. 425-438; Volume 179	
	AD	DOLMETSCH, RICARDO E.; Differential activation of transcription factors induced by CA ²⁺ response amplitude and duration; <i>Nature</i> ; 24 April 1997; pp. 855-858; Vol. 386	
	AE	GOODNOW, CHRISTOPHER C.; Self-Tolerance Checkpoints in B Lymphocyte Development; <i>Advances in Immunology</i> ; 1995; pp. 279-368; Vol. 59	
	AF	GRUMONT, RAELENE J., et al.; Activation of the Mitogen-Activated Protein Kinase Pathway Induces Transcription of the PAC-1 Phosphatase Gene; <i>Molecular and Cellular Biology</i> ; June 1996; pp. 2913-2921; Vol. 16, No. 6	
	AG	GRUMENT, RAELENE J., et al.; Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis; <i>Genes & Development</i> ; 1999; pp. 400-411; Vol. 13	
	AH	HEALY JAMES I., et al; Different Nuclear Signals Are Activated by the B Cell Receptor during Positive Versus Negative Signaling; <i>Immunity</i> ; April 1997; pp. 419-428; Volume 6	
	AI	HEALY JAMES I., et al.; Quantitative and Qualitative control of antigen receptor signaling in tolerant B lymphocytes; <i>Immunological Tolerance</i> ; Novartis Foundation Symposium 215; 1998; pp. 137-145; John Wiley & Sons; England	
	AJ	HONG, JIN XIN, et al.; Isolation and Characterization of a Novel B Cell Activation Gene; <i>The Journal of Immunology</i> ; May 1, 1993; pp. 3895-3904; Vol. 150	
	AK	HUO, LI, et al.; Receptor-Specific Induction of Individual AP-1 Components in B Lymphocytes; <i>The Journal of Immunology</i> ; 1995; pp. 3300-3309; Vol. 154	
	AL	IIDA, SHINSUKE, et al.; Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma; <i>Nature Genetics</i> ; October 1997; pp. 226-230; Vol. 17	
	AM	KUO, CHAY T., et al.; LKLF: A Transcriptional Regulator of Single-Positive T Cell Quiescence and Survival; <i>Science</i> ; 26 September 1997; pp. 1986-1990; Vol. 277	
	AN	LANGDON, WALLACE Y., et al.; The c-myc Oncogene Perturbs B. Lymphocyte Development in Eμ-myc Transgenic Mice; <i>Cell</i> ; October 10, 1986; pp. 11-18; Vol. 47	

Examiner
Signature

P. Ponnaluri


Date
Considered

5/14/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7099509 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

2 of 2

Complete if Known

Application Number	09/747,760
Filing Date	December 21, 2000
First Named Inventor	Glynne, Richard, et. al.
Art Unit	1639
Examiner Name	P. Ponnaluri
Attorney Docket Number	018547-046600US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PP	AO	MARTON, MATTHEW J., et al; Drug target validation and identification of secondary drug target effects using DNA microarrays; <i>Nature Medicine</i> ; November 1998; pp. 1293-1301; Vol. 4, No. 11	
	AP	MASON, DAVID Y., Development and follicular localization of tolerant B lymphocytes in lysozyme/anti-lysozyme IgM/IgD transgenic mice; <i>International Immunology</i> ; 1992; pp. 163-175; Vol. 4, No.2	
	AQ	MITTELSTADT, PAUL R., et al.; Induction of Early Response Genes by Cross-Linking Membrane Ig on B Lymphocytes; <i>The Journal of Immunology</i> ; June 1, 1993; pp. 4822-4832; Vol. 150	
	AR	MITTRÜCKER, HANS-WILLI, et al.; Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function; <i>Science</i> ; 24 January 1997; pp. 540-543; Vol. 275	
	AS	MONROE, JOHN G.; Up-Regulation of c-fos Expression is a Component of the mlg Signal Transduction Mechanism but is not Indicative of Competence for Proliferation; <i>The Journal of Immunology</i> ; March 1, 1988; pp. 1454-1460; Vol. 140	
	AT	NEWTON, JOSHUA S.; B cell early response gene expression coupled to B cell receptor, CD40 and interleukin-4 receptor co-stimulation: evidence for a role of the <i>egr-2/krox20</i> transcription factor in B cell proliferation; <i>Eur. J. Immunol</i> ; 1996; pp. 811-816; Vol. 26	
	AU	PFISTERER, PETRA, et al.; CRIPS-3, a Protein with Homology to Plant Defense Proteins, Is Expressed in Mouse B Cells under the Control of Oct2; <i>Molecular and Cellular Biology</i> Nov. 1996; pp. 6160-6168; Vol. 16, No. 11	
	AV	RATHMELL, JEFFREY, et al.; Repression of B7.2 on Self-reactive B Cells Is Essential to Prevent Proliferation and Allow Fas-mediated Deletion of CD4+ T Cells; August 17, 1998; pp. 651-659; Vol. 188, No. 4	
	AW	SEYFERT, VICKI L.; Differential Expression of a Zinc Finger-Encoding Gene in Response to Positive versus Negative Signaling through Receptor Immunoglobulin in Murine B Lymphocytes; <i>Molecular and Cellular Biology</i> ; May 1989; pp. 2083-2088; Vol. 9, No. 5	
	AX	SLEMMON, J. RANDALL, et al.; Camstatins Are Peptide Antagonists of Calmodulin Based Upon a Conserved Structural Motif in PEP-19, Neurogranin, and Neuromodulin; <i>The Journal of Biological Chemistry</i> ; July 5, 1996; pp. 15911-15917; Vol. 271, No. 27	
	AY	SOLVASON, NANETTE, et al.; Induction of Cell Cycle Regulatory Proteins in Anti-Immunoglobulin-stimulated Mature B Lymphocytes; <i>J. Exp. Med.</i> ; August 1996; pp. 407-417; Vol. 184	
	AZ	SVAREN JOHN, et al.; NAB2, a Corepressor of NGFI-A (Egr-1) and Krox20, Is Induced by Proliferative and Differentiative Stimuli; <i>Molecular and Cellular Biology</i> ; July 1996; pp. 3545-3553; Vol. 16, No. 7	
✓	BA	WICKER, LINDA S., et al.; Suppression of B cell activation by cyclosporin A, FK506 and rapamycin; <i>Eur. J. Immunol</i> ; 1990; pp. 2277-2283; Vol. 20	

Examiner
Signature

P. Ponnaluri

Date
Considered

5/19/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7099509 v1